FindTrial
Sign In

The Diagnostic and Prognostic Value of Presepsin in Sepsis

PRESEPSIN: Biomarker in the Early Diagnosis of Sepsis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06180265
Enrollment
90
Registered
2023-12-22
Start date
2020-02-01
Completion date
2023-07-19
Last updated
2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

septic shock

Brief summary

Intra-abdominal infections are a common cause of sepsis and frequently occur in intensive care unit (ICU) patient. Various markers such as procalcitonin, presepsin and endotoxin are used to identify patients at risk of sepsis or to guide proper treatment. No studies compared presepsin to procalcitonin and endotoxin in patients treated with by extracorporeal hemoperfusion with a polymyxin-B-adsorbing cartridge (PMX-HA).

Detailed description

Intra-abdominal infections are a common cause of sepsis and frequently occur in intensive care unit (ICU) patient. Various markers such as procalcitonin, presepsin and endotoxin are used to identify patients at risk of sepsis or to guide proper treatment. Particularly, endotoxin can be removed from the blood by extracorporeal hemoperfusion with a polymyxin-B-adsorbing cartridge (PMX-HA). No studies compared presepsin to procalcitonin and endotoxin in patients treated with PMX-HA. The investigators aim to evaluate the trend and prognostic value of presepsin versus procalcitonin and endotoxin in ICU patients with septic shock from complicated major abdominal surgery, treated with PMX-HA.

Interventions

DIAGNOSTIC_TESTpresepsin, procalciton, endotoxin

measurement of presepsin, procalciton, endotoxin plasmatic levels

Sponsors

University of Foggia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* caucasian patients * patients undergoing laparoscopic major abdominal surgery

Exclusion criteria

* pregnancy, * organ transplantation, * palliative care * metastatic cancer * head trauma and polytrauma * coagulopathies * use of anticoagulants * neurological disease * autoimmune disease * thyroid disease.

Design outcomes

Primary

MeasureTime frameDescription
incidence of mortality at 30-daysup to 30 daysincidence of mortality

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026